Special Issue "Biomarkers in Blood"


A special issue of Diagnostics (ISSN 2075-4418).

Deadline for manuscript submissions: 25 March 2015

Special Issue Editor

Guest Editor
Prof. Dr. Ludmilla A. Morozova-Roche
Department of Medical Biochemistry and Biophysics, Umeå University, Umeå, SE 90781, Sweden
Website: http://www.medchem.umu.se/english/research/principal-investigators/morozova-roche/
E-Mail: ludmilla.morozova-roche@medchem.umu.se
Phone: +46907865283
Fax: +46 90 786 9795
Interests: amyloid; protein folding; neurodegeneration; inflammation; amyloid diseases

Special Issue Information

Dear Colleagues,

The issue "Biomarkers in Blood" will be focused on the diagnostics of plethora of pathologies, including such widely spread ailments as cancer, neurodegenerative Alzheimer’s, Parkinson’s and other diseases as well as other pathological conditions, by using biomarkers in the blood. Due to growing elderly population these diseases are on the rise in the modern society and combatting them is a global issue. The early or even pre-clinical diagnostics of pathological conditions at the stage when the clinical symptoms are not obvious would be of significant therapeutic value and would enable to administer protective or preventive treatments at an earlier stage. The molecular constitution of blood can be highly representative of the physiological state of an individual. Patient blood serum analyses are potentially minimally invasive and cheap means of both early disease detection and the convenient monitoring of disease response to therapeutic intervention. These approaches are tightly aligned with the concept of personalised healthcare. Over last years a range of new robust diagnostic assays underpinning the presymptomatic detection of pathological conditions were established as well as a range of new biomarkers associated with the disease pathology were discovered. The biodiagnostics is a rapidly expanding field and yet many problems need to be solved. Experience shows that candidate biomarkers may fail to demonstrate their clinical utility, which can be because they are genuinely not relevant to the disease, or their validation has been limited to a subset of patients to whom they are relevant, or the technical limitations of the detection methods.
The present issue aims at bringing a collection of research and reviewer articles together to summarize a state of the art, problems and future directions in the biomarker and biodiagnostics field based on the blood analysis. Your contribution is very welcome!

Yours faithfully,

Prof. Dr. Ludmilla Morozova-Roche
Guest Editor


Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.


  • biomarker
  • biosensor assay
  • diagnostics
  • blood analysis
  • presymptomatic detection
  • disease monitoring
  • cancer
  • neurodegenerative diseases

Published Papers (3 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-3
p. 10-26
by , , , ,  and
Diagnostics 2015, 5(1), 10-26; doi:10.3390/diagnostics5010010
Received: 10 October 2014 / Accepted: 19 December 2014 / Published: 12 January 2015
Show/Hide Abstract | PDF Full-text (1108 KB) | HTML Full-text | XML Full-text | Supplementary Files
(This article belongs to the Special Issue Biomarkers in Blood)
p. 1-9
by , , , , ,  and
Diagnostics 2015, 5(1), 1-9; doi:10.3390/diagnostics5010001
Received: 15 September 2014 / Accepted: 20 November 2014 / Published: 5 January 2015
Show/Hide Abstract | PDF Full-text (691 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Biomarkers in Blood)
p. 153-164
by  and
Diagnostics 2014, 4(4), 153-164; doi:10.3390/diagnostics4040153
Received: 9 September 2014 / Revised: 8 October 2014 / Accepted: 11 October 2014 / Published: 22 October 2014
Show/Hide Abstract | PDF Full-text (683 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Biomarkers in Blood)
Select/unselect all
Displaying article 1-3
Select articles Export citation of selected articles as:

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Pain in the blood? Envisioning mechanism-based diagnoses and biomarkers in clinical pain medicine
Author: Emmanuel Bäckryd
Affiliation: Rehabilitation Medicine, Department of Medicine and Health Sciences, Linköping University, SE 581 85 Linköping, & Pain and Rehabilitation Centre, UHL, County Council of Östergötland, SE 581 85 Linköping, Sweden
Abstract: Chronic pain is highly prevalent, and pain medicine lacks objective biomarkers to guide diagnosis and choice of treatment. The current US “opioid epidemic” is a reminder of the paucity of effective and safe treatment options. Traditional pain diagnoses according to the International Classification of Diseases are often unspecific, and analgesics are often prescribed on a trial-and-error basis. In contrast to this current state of affairs, the vision of future mechanism-based diagnoses of chronic pain conditions is presented in this non-technical paper, focusing on the need for biomarkers and the theoretical complexity of the task. Pain is and will remain a subjective experience, and as such is not objectively measurable. Therefore, the concept of “noci-marker” is presented as an alternative to “pain biomarker”, the goal being to find objective, measurable correlates of the pathophysiological processes involved in different chronic pain conditions. This vision entails a call for more translational pain research in order to bridge the gap between clinical pain medicine and preclinical science.

Title: Inverse Relationship of Bone Mineral Density and Serum Level of N-terminal Pro-B-type Natriuretic Peptide in Peritoneal Dialysis Patients
Authors: Bang-Gee Hsu, Chung-Jen Lee, Hung-Hsiang Liou, Chih-Hsien Wang, Jen-Pi Tsai
Abstract: Studies have shown that elevated serum N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is an independent predictor of adverse outcome in congestive heart failure and hemodialysis patients. The natriuretic peptides are potent lipolytic agents that act in adipose tissue and influence bone mineral density (BMD). In dialysis patients whose BMD are lower had worse outcome. This study evaluated the relationship between BMD and fasting serum concentration of NT-pro-BNP in peritoneal dialysis (PD) patients. Fasting blood samples were obtained from 52 PD patients. BMD was measured by dual energy X-ray absorptiometry of the lumbar vertebrae (L2–L4). Serum NT-pro-BNP level was measured by an electrochemiluminescence immunoassay. There are 10 patients (19.2%) diagnosed to have osteoporosis, 23 patients (44.2%) have osteopenia, and 19 patients have normal BMD. Patients who have lower T-score have older age (p = 0.012), lower body mass index (p = 0.006), shorter body height (p = 0.018), and lower body weight (p = 0.010), but have higher serum serum NT-pro-BNP (p < 0.001). There was no association between BMD with sex, menopausal status, PD modality, diabetes mellitus, or hypertension. After adjusting with age, body height, body weight, BMI, and NT-pro-BNP by multivariate forward stepwise linear regression analysis, high serum level of NT-pro-BNP (R2 change = 0.342; p < 0.001) and low body weight (R2 change = 0.188; p = 0.001) were independently associated with lower lumbar BMD. In this study, we found that higher serum level of NT-pro-BNP and low body weight of PD patients are associated with lower BMD.

Last update: 16 January 2015

Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert